Beginning of closed period before publication of quarterly results
21.05.2026
See also
Synektik one step closer to planned division
- Corporate news
- Investor relations
Synektik shareholders have unanimously approved the division of the company and spinoff of the cardiotracer project to Syn2bio
- Corporate news
- Investor relations
KNF has approved the Syn2bio prospectus. The debut on the WSE is planned for April
- Corporate news
- Investor relations